Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma
Clinical trial NCT05064358 · COMPLETED
Trial details
- NCT number
- NCT05064358
- Sponsor
- GlaxoSmithKline
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-03-03
- Primary completion
- 2024-08-19
- Enrollment
- 177
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.